key: cord-0722451-fy7ds05e
authors: Rahman Oany, Arafat; Mia, Mamun; Pervin, Tahmina; Junaid, Md.; Zahid Hosen, S.M.; Moni, Mohammad Ali
title: Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics
date: 2020-09-25
journal: Int J Antimicrob Agents
DOI: 10.1016/j.ijantimicag.2020.106177
sha: 02623f0165c11ed10b4cee6ecb5c10913bca9851
doc_id: 722451
cord_uid: fy7ds05e

To date, the pandemic of COVID-19 causes 11.8 million cases and about 545481 deaths in the world. In this study, we have employed virtual screening approaches and selected 415 lead-like compounds from 103 million chemical substances, based on the existing drugs, from PubChem databases as potential candidates for the S protein-mediated viral attachment inhibition. Thereafter, based on drug-likeness and Lipinski's rules, 44 lead-like compounds were docked within the active side pocket of the viral-host attachment site of the spike protein. Corresponding ligand properties and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profile were measured. Furthermore, four novel inhibitors were designed and assessed computationally for its efficacy. From the comparative analysis, we found that our screened compounds maintain better results than the proposed mother compounds VE607 and SSAA09E2. The designed four novel lead compounds possessed more fascinating output without deviating any of the Lipinski's rules. They also showed higher bioavailability and the drug-likeness score of 0.56 and 1.81 respectively compared to the mother compounds. All the screened compounds and novel compounds showed promising ADMET properties. Among them, the compound AMTM-02 was the best candidate through considering comparative analysis with a docking score of -7.5 kcal/mol. Furthermore, the binding study was verified by molecular dynamics simulation over 100ns by assessing the stability of the complex. Thus, we hope that our proposed screened compounds, as well as the novel compounds may give some breakthroughs for the development of a therapeutic drug to treat SARS-CoV-2 proficiently in vitro and in vivo.

During the past two decades, the world has been facing bitter health experiences from the major outbreaks of coronaviruses (CoVs) with mild to severe human respiratory tract infections. The first global outbreak covered five continents with over 8,000 infected cases and a mortality rate of 10% by severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 [1] [2] [3] [4] [5] [6] [7] . During 2012, the second outbreak carried out in Saudi Arabia by middle east respiratory syndrome coronavirus (MERS-CoV) with a high mortality rate of 35% [8, 9] . The third human pathogenic coronavirus, 2019 novel coronavirus (2019-nCoV), was first identified at the end of 2019 in Wuhan, China with atypical pneumonia [10] and subsequently spreads to the whole world within 3-4 months. The 2019-nCoV has already been exceeded all of the previous histories of SARS-CoV and MERS-CoV in terms of its transmission rate [11] and the case fatality rate (2.3%) [12] . The fatality rate becomes higher in elderly patients and patients with comorbidities [13] . According to the World Health Organization (WHO), the virus and disease names are respectively, COVID-19 virus and Coronavirus Disease 2019 [14] while the International Committee on Taxonomy of Viruses (ICTV) renamed the virus as SARS-CoV-2 [15] . According to the WHO "situation report 171" (reported on 10 July 2020), a total of 11 874 226 confirmed cases of SARS-CoV-2 were reported, including 545 481 deaths worldwide from 213 countries and/or territories [16] . As the situation is getting worse day by day globally and appropriate treatment strategies are unavailable, it is an emergency demand to develop an antiviral/therapeutic drug immediately in the scientific world.

The SARS-CoV-2 belongs to the virus family Coronaviridae [17] and has 79.5% genome identical to SARS-CoV [18] . The four structural proteins-spike (S), envelop (E), membrane (M), and nucleocapsid (N) are encoded by the genome of SARS-CoV-2 as the similar fashion of SARS-CoV [19] . Trans-membrane trimeric S protein comprises of two functional subunits-S1 and S2 [20] , whereas S1 harbors the binding activity to the receptor of host cells and S2 is responsible for the host-viral cell fusion [21] . The entry of SARS-CoV-2 into host cells is closely identical to the binding mode of the SARS-CoV and the S proteins" receptorbinding domain (RBD) [22] maintains a high affinity to the human receptor Angiotensin-Converting Enzyme 2 (ACE2) [23, 24] . Cryo-EM structure analysis reported that 319 to 591 of S residues of 2019-nCoV RBD-SD1 fragment showed a stable folding conformation with the ACE2 receptor binding [25] . Apart from SARS-CoV, SARS-CoV-2 has a novel feature at the S1/S2 boundary of S protein with an unexpected furin cleavage site generated through the insertion of 12 nucleotides [23, 25] . In S1 subunit of SARS-CoV-2, a total of six RBD amino acids L455, F486, Q493, S494, N501, and Y505 have shown a critical role for binding to ACE2 receptors [24] . Recent structural analysis revealed highly conserved residues in 2019-nCoV S RBD compare to SARS-CoVS RBD, which are critical for ACE2 receptors binding [22] . Therefore, the blocking of 2019-nCoV S protein from binding to human ACE2 receptors is the most promising target to develop a novel therapeutic drug in the current pandemic situation. A few numbers of previous studies designed some novel therapeutic drugs for SARS-CoV targeting the mode of action of S protein-mediated entry to host cell. In the present study, we have tried to design novel inhibitors of viral attachment through virtual screening to combat this deadly virus.

The NCBI database was initially explored to find out the spike glycoprotein of SARS_CoV-2

[29]. Initially, 14were selected for the study and stored as a FASTA format for further analysis. 

To get insight into the domain structure of the S protein Pfam program of the Sanger Institute

[33] and for the identification of motifs, we used ScanProsite of the Swiss Institute of Bioinformatics [34]. Accession No. QHR63290 was used for this analysis and further proceeded with this protein.

Homology models of the target were done by MODELLER v9 [35] and the top-scoring template were selected for the model construction. Then the predicted models were employed for the validation through the PROCHECK [36] tools of the SWISS-MODEL Workspace [37] . To check the further quality of the predicted model, the superposition between the structure and template was also performed.

The electrostatic potential of the predicted model was built by APBS [38] server through transforming .pdb to .pqr file and the visualization was done by PyMOL molecular graphics system [39] . For further securing the validation of the predicted models, the energy minimization was also done. The GROMOS 96 [40] force field was used for the minimization of the structure.

The active sites of the final proposed model were constructed by the CASTp server. This server builds a model through the pocket algorithm of the alpha shape theory [ 

Ligand structural and behavioral properties were analyzed for the cross-validation of the ligands as a suitable therapeutic candidate. Wide ranges of properties were analyzed 

Novel leads were designed based on the screening results with the aid of PubChem Sketcher V2. 4 [52] . The designed structure was then fetched as Canonic SMILES format. Then threedimensional structures were generated by Open Bable toolbox [43] . The Ligand properties, molecular docking, and ADMET analysis of the novel compounds were also assessed as described earlier.

To identify the changes in the structural conformation, interaction pattern, and binding stability of the ligand-protein complex, we employed YASARA Dynamics software [53] for all molecular dynamics (MD) simulation by using AMBER14 as a force field [54]. The best protein-ligand complex provided by molecular docking computations was selected for further analysis. In this prospect, a simulation cell was generated in a clean and optimized system, where the box size was 90 × 90 × 90 Å 3 and our protein-ligand complex placed inside it.

Transferable intermolecular potential 3 points or TIP3P model was applied, and Na/Cl ions were added in replacement of water to give a total NaCl concentration of 0.9% where the entire solvent molecules were 132889 and density was 0.997 g/ml, the temperature 298 K and pH maintained at 7.4 [55, 56] . For better clarity, we omitted the rendering of water molecules. Then, the energy minimization of each system has been implemented by a simulated annealing method using the steepest gradient approach (5000 cycles). For longrange electrostatic interactions, Particle Mesh Ewald method (PME) summation was employed with a cut-off value of 8 Å. Subsequently, by using a step-size equivalent to 2.5 fs, the manufacturing MD simulation was operated at YASARA force field level around 100 ns time scale run at a constant pressure and temperature by employing a Berendsen Thermostat and constant pressure [57, 58] . An assessment of the MD trajectories was saved every 25 ps.

This trajectory was used further for the analysis to estimate the structural changes and stability employing Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF) using YASARA structure built-in macros [59].

Phylogenetic analysis of all the strains of the S protein was generated from CLC Sequence Viewer v7.0.2 and is depicted in Figure 1 with an appropriate branch distance. The 1000 bootstrap was used to generate the tree. The multiple sequence alignment generated from the Jalview v2 tool was shown in Figure 2 . In this figure, we only showed our sequence of interest, RBD, in the MSA with appropriate conservation information throughout the sequences.

The major domain and motif organization of the S protein, based on the sequence information from the Pfam and ScanProsite, was constructed and depicted in Figure 3 . Accession No. QHR63290, with a sequence length of 1273 amino acid residue was used to generate the construct.

A homology model of the targeted protein was constructed through MODELLER and is illustrated in Figure 4a . The superposition between the template and model was shown in 

The electrostatic potentiality of the modeled protein was analyzed for the identification of the energy distribution of the protein and showed in Figure 5a . The GROMOS 96 force field was applied to the modeled protein for better model construction. The force-field energies of the modeled protein before and after minimization were -44342.816 and -57854.49 kJ/mol, respectively. The energy distribution of the protein after minimization is shown in Figure 5b .

CASTp server predicted different active sites of our preferred protein with different volume scores and we picked the best two large volumes as the final active sites ( Figure. 6a and 6b) .

The molecular surface areas of the active sites were 31662.48 and 311.61, respectively.

PubChem database, depositor of 103 million depositor-provided chemical substances, initially explored for the viral attachment inhibitors of the S protein. Based on the potential inhibitor VE607 and SSAA09E2, we initially screened a total of 415 lead-like compounds (Table S1) . Thereafter, based on drug-likeness and Lipinski"s rules, we have finally selected 46 lead-like compounds for docking including VE607and SSAA09E2 ( Figure S1 ). For the binding energy of docking poses, RMSD values of 0.0 were selected, and interacting amino acid residues are illustrated in Figure 7 . The docking analysis results are shown in Table 1 .

Different properties of the screened compounds, including drug-likeness, Lipinski"s rules, aqueous solubility, and bioavailability, were assessed for the identification of the best therapeutic candidates ( Table 2 ). All the ADMET properties were also assessed for the selected ligands and cross-checked with different servers and tools for the validity of the results. These properties are described in Table 3 .

Based on the screening results novel leads were designed from PubChem Sketcher V2.4 and are shown in Figure 8a . The ligand properties of the novel drug are shown in Table 4 .

Interaction analysis from the molecular docking is illustrated in Figure 8b and within the active site pocket in Figure 8c . The ADMET profile is described in Table 5 .

To understand the stability, flexibility, structural behavior, and binding mechanism of the best protein-ligand complex along with the apo form of protein, we have carried out 100 ns of molecular dynamics simulations. Here we considered our top designed novel compound, AMTM-02, with the spike protein.

The atomic RMSDs of the protein-ligand complex along with the apo form of protein were calculated and plotted in a time-dependent manner in Figure 9 a, where the apo form and the protein-ligand complex indicated with the red and blue color, respectively. According to The protein-ligand complex showed little bit higher fluctuations at 450-500 residues compared to apo.

With the progression of the SARS-CoV-2 throughout the world, the death rate is being surprisingly high. The scientific communities are working hard to develop some therapeutics such as vaccines or drugs [19, [60] [61] [62] [63] . Computational biology approaches are becoming very much promising for treating many severe diseases through projecting the in vitro validations

The spike glycoprotein is one of the most significant targets for designing therapeutics against CoV and thought to be more prone to mutations [69] . In our study, we have retrieved 14 S proteins and the phylogenetic study showed that they were more closely related ( Figure   01) . Furthermore, the MSA study revealed that the RBD sequences from different strains were mostly conserved (Figure 02 ) and supporting the choice of target for therapeutic development. The RBM within the RBD (Figure 03) is crucial for binding with host cell receptor and is typically a tyrosine-rich region [70] .

With 95.06% amino-acid residues in the most favorable region, the validation of the homology model through "Ramachandran Plot" favors a comparatively good model.

Additionally, the superposition RMSD value (0.202) between the predicted structure and template has also supported the validity of the structure.

The three-dimensional representation of the RBD and RBM also helps us to get an insight into the attachment site of the ACE2 (Figure 04) . The electrostatic potential of the protein revealed its charges throughout the surfaces and the positive charges (blue) in the RBM region indicate the hydrophobicity of that region (Figure 05) .

Active site analysis of the targeted protein is an important part of drug designing approaches.

As we are looking for the attachment inhibitors, hence we selected the second-largest volume of the active site having the surface area of 311.61 (Figure 7b) .

From the extensive literature review, we found that the compounds VE607 and SSAA09E2

were the most reported attachment inhibitors of the SARS-CoV spike protein. From that point of view, we have screened 415 lead-like compounds from PubChem database. From the comparative analysis, we found most of the docked compounds, total 44, were potent inhibitors of the viral attachment of SARS-CoV-2 ( Table 2, Table 3and Figure 8 ).

Finally, we reinforce to design novel inhibitors based on the previous findings and found four novel compounds having optimistic lead-like properties compared with VE607 and SSAA09E2. The compounds were named as AMJM 01 to 04.

From the ligand properties, we found VE607 violates one of the Lipinski"s rules of five through having its 10 rotatable bonds. The ADMET properties disclosed that the VE607 possesses the blood-brain barrier (BBB) permeability which might be toxic to the central nervous system (CNS). Additionally, both VE607 and SSAA09E2 have P-glycoproteininhibitor properties, which should lead to drug accumulation related toxicity to the body.

The binding energies with the protein for VE607 and SSAA09E2 were -6.1 and -6.7

kcal/mol, respectively. In the case of novel compounds, the binding energy ranged from -6.7 to -7.5 kcal/mol ( Table 04) Finally, the MD simulation study of the targeted protein and the novel designed compound AMTM 02, have further strengthened our prediction through validating the complex interaction stability presented by RMSD value (Figure 9a) . The RMSF values of the single protein and the complex have also been observed, and few higher fluctuations observed in the looped regions of the protein (Figure 9b) .

From the aforementioned comparative study, we can easily demonstrate that the proposed novel compounds might have some significant outputs for drug discovery. However, these analyses require several in vitro and in vivo validations before formulating the drug to resist SARS-CoV-2.

At the moment, the biggest challenge for the world is to escape from the pandemic SARS-CoV-2 due to the inadequacy of effective therapeutic drugs or vaccines. The designed novel inhibitors in the present study for the S protein of SARS-CoV-2 not only showed the higher characteristics in terms of drug-likeness properties but also have the best binding affinities to the target protein from blocking the viral attachment with the host cells. However, these analyses require several in vitro and in vivo validations before formulating the drug to resist SARS-CoV-2. 

Coronaviruses-drug discovery and therapeutic options

A novel coronavirus associated with severe acute respiratory syndrome

Coronavirus as a possible cause of severe acute respiratory syndrome. The Lancet

The genome sequence of the SARS-associated coronavirus

Characterization of a novel coronavirus associated with severe acute respiratory syndrome. science

Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection

A major outbreak of severe acute respiratory syndrome in Hong Kong

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Commentary: Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group

A novel coronavirus from patients with pneumonia in China

Coronavirus disease 2019 (COVID-19): situation report

SARS-CoV-2: virus dynamics and host response. The Lancet Infectious Diseases

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

COVID-19) and the virus that causes it

Severe acute respiratory syndrome-related coronavirus-The species and its viruses, a statement of the Coronavirus Study Group

Coronavirus disease 2019 (COVID-19): situation report

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-The latest 2019 novel coronavirus outbreak in Wuhan

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Subunit vaccines against emerging pathogenic human coronaviruses